Our laboratory has been investigating the immunobiology of the Neisserial porin PorB for the last two decades. We first began by investigating the use of this protein as a potential anti-Neisserial candidate, but through this work we found that this protein had unique immune stimulatory abilities above and beyond its own potential use as a vaccine. We found that PorB can be used as an immune adjuvant for vaccines and that this ability was directly related to its ability to stimulate antigen presenting cells (APC) and increase expression of the costimulatory molecule CD86 and class II MHC. Moreover, we found that the ability of PorB to stimulate and activate antigen presenting cells was directly due to an interaction with the pattern recognition receptor, TOLL-like Receptor 2 (TLR2) and requires the TLR adaptor protein MyD88. We have further shown, as described in the preliminary data section and in that TLR2 needs to heterodimerize with TLR1 (and not TLR6) in order for PorB to stimulate these APCs. Utilizing this body of information, the next logical step for studying the immune stimulating adjuvant activity of PorB is to compare this activity to other known vaccine adjuvants. This will allow for the better use of PorB as adjuvant, by understanding what type of immune response it induces as compared to these other adjuvants. Moreover, we believe it is essential to continue to investigate the adjuvant potential of PorB, as it is currently the only TLR2 ligand being investigated as a vaccine adjuvant. We shall compare the immune stimulation by PorB to panel of other adjuvants, including the only licensed adjuvant, Alum (inflammasomes mediated immune activation, other TLR ligands, including CpG DNA (TLR9), and monophosphoryl lipid A (MPL)(TLR4), and QS-21. We shall examine the ability of these adjuvants to induce immune responses to a test antigen, ovalbumin, which we have used previously as described in the Preliminary Data section. We shall measure antibody levels induced, isotypes and IgG subtypes induced, antibody affinity, CD4 T cell response and ability to induce APC migration and lymph node specific T cell stimulation. Moreover, we shall compare the ability of these different adjuvants to protect mice from infection with Listeria which secretes OVA. This is a well characterized model and has been used previously to demonstrate that the presence of OVA specific CD4 and CD8 T cells are necessary for protection of mice from infection with this pathogen when it is constructed to secrete OVA. We shall obtain this strain from Dr. Darren Higgins in the Dept. of Microbiology at the Harvard Medical School, who has significant expertise in this model and will act as a consultant on this proposal. Even though the protection induced by most licensed vaccines are due to the induction of neutralizing or functional antibodies, we feel it would extremely important to begin to definitively compare the ability of these adjuvants, including PorB, to not only induce functional antibodies, but to potentially induce a protective CD8 CTL response.
We have shown that the Neisserial porin, PorB, is a potent immune adjuvant and works via recognition by TLR2 and induction of antigen presenting cell activation. This proposal will examine the adjuvant activity of PorB and compare this activity to other currently investigated adjuvants (including Alum, CpG DNA, MPL and QS-21). We shall examine induction of both humoral responses and CD8 T cell responses and the ability of the vaccines to prevent Listeria infection in mice. Moreover, we shall further examine the mechanism of PorB adjuvant activity via the use of MyD88 floxed mice bred with mice expressing cell specific cre recombinase.
Showing the most recent 10 out of 25 publications
